A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma
- Promotore
- Amgen Inc
- Acronimo
- ABP 206 (258026_20210031_Amgen Inc.)
- Struttura
- Mesotelioma
- Sperimentatore principale
- Cerbone Luigi
- Stato arruolamento
- In attesa di arruolamento